Botulinum toxin treatments of neurological and neuropsychiatric disorders

• US 10,064,921 B2
• Filed: 03/02/2017
• Issued: 09/04/2018
• Est. Priority Date: 10/29/2003
• Status: Expired due to Fees

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Blumenfeld, Andrew M.
• Primary Examiner(s): Emch, Gregory S
• Application Number:
  US15/447,770
• Publication Number:
  US 20170173123A1
• Time in Patent Office: 551 Days
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C12Y 304/24069 Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Abstract

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.

Claims

1. A method for treating a post-traumatic stress disorder in a patient in need thereof, comprising directly administering a botulinum toxin to a trigeminal nerve of the patient, thereby treating the post-traumatic stress disorder.

2. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.

3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type B.

4. The method of claim 1, wherein the method of local administration is injection.

5. The method of claim 1, wherein the administering is by non-intramuscular injection.

6. The method of claim 1, wherein the administering is subdermal, intradermal or transdermal.

7. The method of claim 1, wherein the trigeminal nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.

8. A method for reducing the occurrence of a symptom of post-traumatic stress disorder in a patient with post-traumatic stress disorder, the method comprising locally administering a therapeutically effective amount of a botulinum toxin to a trigeminal sensory nerve or to the vicinity of a trigeminal sensory nerve of the patient, thereby reducing the occurrence of a symptom of post-traumatic stress disorder, wherein the administering is non-intramuscular.

9. The method of claim 8, wherein the botulinum toxin is botulinum toxin type A.

10. The method of claim 8, wherein the botulinum toxin is botulinum toxin type B.

11. The method of claim 8, wherein the method of local administration is injection.

12. The method of claim 8, wherein the administering is by subdermal, intradermal or transdermal.

13. The method of claim 8, wherein the administering is subdermal.

14. The method of claim 8, wherein the therapeutically effective amount of the botulinum toxin administered is between about 1 unit and about 3,000 units.

15. The method of claim 8, wherein the trigeminal sensory nerve is selected from the group consisting of an ophthalmic nerve, maxillary nerve, mandibular nerve, supra orbital nerve, supra trochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve and a greater occipital nerve.